01548 GENSCRIPT BIO
- 12.380
- -0.080-0.64%
GENSCRIPT BIO News
Changes in Hong Kong stocks | CRO concept stocks are generally weakening, and many companies have responded once again by overwhelmingly passing the new US Biosafety Act
The Zhitong Finance App learned that CRO concept stocks have generally weakened. As of press release, Tiger Pharmaceuticals (03347) fell 3.3% to HK$35.15; Kingsley Biotech (01548) fell 1.44% to $12.28; Pharmaceutical Kangde (02359) fell 1.21% to $40.7; and Gloria Ying (06821) fell 0.94% to $63.55. According to the news, on the morning of May 15, local time, the US House of Representatives passed the new “Biosafety Act” with a 40-1 vote in a subordinate committee hearing. The new version of the Act requires the companies involved to have existing contracts/products
Legend Biotech's Loss Narrows in Q1 as Revenue Surges
Genscript Biotech's (HKG:1548) Nasdaq-listed subsidiary Legend Biotech reported a loss of $59.8 million, or $0.16 per share, in the first quarter, down from $112.1 million, or $0.34 per share, a year
Trending Industry Today: WUXI APPTEC Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
May 14th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 9 constituents up and WUXI APPTEC leading Gains.$WUXI APPTE
Changes in Hong Kong stocks | CRO concept stocks had the highest increase in the new US bill introducing an 8-year exemption period, and negative risks of short-term overseas policies were implemented
The Zhitong Finance App learned that CRO concept stocks had the highest gains. As of press release, Yao Ming Kangde (02359) rose 6.28% to HK$42.3; Pharmaceutical Biotech (02269) rose 5.52% to HK$14.92; Kingsley Biotech (01548) rose 4.86% to HK$12.52; Kanglong Chemical (03759) rose 4.93% to HK$11.5. According to the news, last Friday local time, Brad R. Wenstrup, a Republican member of the US House of Representatives, initiated a new version of the Biosafety Act (H.R. 8333).
Genscript Biotech Corporation's (HKG:1548) Stock Price Dropped 3.9% Last Week; Private Companies Would Not Be Happy
Key Insights The considerable ownership by private companies in Genscript Biotech indicates that they collectively have a greater say in management and business strategy A total of 5 investors have
Hong Kong Stock Announcement Nuggets | Tencent Music-SW Announces First-Quarter Results Net Profit attributable to equity holders of 1.42 billion yuan, up 23.9% year-on-year
China Resources Land (01109)'s cumulative contract sales amount for the first 4 months was about 72 billion yuan; China Life Insurance (02628)'s original insurance premium income for the first 4 months was about 371.2 billion yuan, up 3.9% year-on-year
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 31 MARCH 2024 OF A LISTED SUBSIDIARY - LEGEND BIOTECH CORPORATION
Trending Industry Today: WUXI BIO Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
May 6th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 8 constituents up, 1 constituents down and WUXI BIO leading
Changes in Hong Kong stocks | CRO concept stocks continue to rebound, the downstream demand side needs to improve, and domestic CXO companies still have a competitive advantage
CRO concept stocks continued to rebound. As of press release, Viva Biotech (01873) rose 8.93% to HK$0.61; Kingsley Biotech (01548) rose 8.35% to HK$11.94; Kanglong Chemical (03759) rose 5.91% to HK$10.04; and Pharmaceutical Biotech (02269) rose 5.79% to HK$14.26.
Is There Now An Opportunity In Genscript Biotech Corporation (HKG:1548)?
Genscript Biotech Corporation (HKG:1548), might not be a large cap stock, but it saw significant share price movement during recent months on the SEHK, rising to highs of HK$17.28 and falling to
Trending Industry Today: TIGERMED Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
April 26th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 8 constituents up and TIGERMED leading Gains.$TIGERMED(03
BOC International: Maintaining Kingsley Biotech's (01548) “Buy” Rating Target Price of HK$27.75
Kingsley Biotech (01548) guides strong annual revenue growth of 15%-20% and 20%-30% (@CER, i.e. Comparative Effects Study).
Kingsley Biotechnology (01548.HK): The European Commission approved CARVYKTI for second-line treatment of patients with recurrent refractory multiple myeloma
Gelonghui, April 23 | Kingsley Biotech (01548.HK) issued an announcement. On April 22, 2024, Legend Biotech issued a press release announcing that the European Commission (EC) approved CARVYKTI (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with recurrent and refractory multiple myeloma. These patients have received at least one treatment in the past, including proteasome inhibitors (PI) and immunomodulators (IMID). The patients showed disease progression during the last treatment , and lenalidomide is difficult to treat
金斯瑞生物科技：2023年度報告
Kingsley Biotechnology (1548.HK): Global layout, business blossoming, innovative drug business entering a commercialization period
Under the intertwined influence of the risk factors of globalization, how can enterprises persevere and continue to move forward in the midst of turbulence has become a common problem in the industry. However, Kingsley seemed to have given his own unique answer with an excellent questionnaire.
Trending Industry Today: GENSCRIPT BIO Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
April 19th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending lower today with 9 constituents down and GENSCRIPT BIO leading Losses.$GENS
Changes in Hong Kong stocks | CRO concept stocks continue to decline, the Federal Reserve does not rule out possible interest rate hikes, domestic innovative drugs are still in an adjustment cycle
The Zhitong Finance App learned that CRO concept stocks continued to decline. As of press release, Tiger Pharmaceuticals (03347) fell 7.94% to HK$28.4; Kingsley Biotech (01548) fell 5.93% to HK$10.78; Kanglong Chemical (03759) fell 4.83% to HK$8.47; and Pharmaceuticals (02359) fell 4.5% to HK$32.9. According to the news, overnight, Federal Reserve officials made hawkish remarks. New York Federal Reserve Chairman Williams said that if the data reminds us that we need to raise interest rates to achieve our goals, then we will obviously do it. Furthermore, Asia
Kingsley Biotech: CARVYKTI's net trade sales in the first quarter were about US$157 million
Kingsley Biotech (01548) issued an announcement. On April 16, 2024, Legend Biotechnology Co., Ltd. (Legend Biotech) announced that according to Legend Biotech and Janssen Biotech, Inc. (Janssen) signed a cooperation and licensing agreement on December 21, 2017
Changes in Hong Kong stocks | Kingsley Biotech (01548) fell more than 5%, and the company's stock price hit a new low in recent years. CDMO short-term demand growth and profitability were under pressure
Kingsley Biotech (01548) fell by more than 5%, down 5.59% at press time, to HK$11.48, with a turnover of HK$104 million.
Changes in Hong Kong stocks | Kingsley Biotech (01548) is now up nearly 5% legendary biotech CARVYKTI approved by FDA for second-line treatment of multiple myeloma
The Zhitong Finance App learned that Kingsley Biotech (01548) is now up nearly 5%. As of press release, it has risen 4.75% to HK$13.22, with a turnover of HK$840.661 million. According to the news, Legendary Biotech announced on April 5 that the US Food and Drug Administration (FDA) has approved CARVYKTI (Sidakiolenol) to treat patients with recurrent or refractory multiple myeloma (RRMM). These patients have received at least first-line treatment (including proteasome inhibitors and immunomodulators) and are resistant to lenalidomide. Guolian Securities pointed out that considering 2023 CARVYKTI
Analysis
Price Target
No Data
